REG - ValiRx PLC - Directorate Changes

ValiRxAnnouncement

25/07/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240725:nRSY7420Xa&default-theme=true

RNS Number : 7420X  ValiRx PLC  25 July 2024

ValiRx plc

 

("ValiRx" or the "Company")

 

Directorate Changes

 

ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on
early-stage cancer therapeutics and women's health, is pleased to announce
that Martin Gouldstone, a current Independent Non-Executive Director of the
Company, has been appointed Independent Non-Executive Chairman with immediate
effect.

 

In addition, the Company announces that Cathy Tralau-Stewart has been
appointed to the Board as Executive Director with immediate effect and Dr Mark
Eccleston is proposed to the join the Board as Chief Executive Officer subject
to standard regulatory due diligence.

 

Dr Mark Eccleston

 

Mark has worked as a scientific consultant and served on both the Commercial
and Scientific Advisory Boards of ValiRx and Inaphaea gaining comprehensive
knowledge of the Company's development programmes.

 

With over 30 years' experience working in translation science in both drug and
biomarker development, Mark is a former BBSRC Enterprise fellow and holds an
MBA (Entrepreneurship). He is an inventor of 26 published patents ranging from
peptide and CAR-T cell therapies to nucleosome enrichment as well as
biodegradable chewing gum.

 

Mark is the Managing Director of OncoLytika Ltd, a UK based technology
consultancy company with a successful track record of securing grant funding
(close to €3 million in Eurostar funding), strategic business development
and client project management. He is also a scientific founder of several
companies, including Volition, US listed biomarker company established as a
spin out from ValiRx which reached a peak valuation of over $250 million. Mark
currently serves as an independent scientific advisor supporting Nu.Q®️
Discover services and sits on Volition's Scientific Advisory Board as well as
being a shareholder.

 

In addition to his commercial activities, Mark has supervised multiple
industry funded PhD and Masters students at various universities, including
the Open University, Greenwich University and DKFZ in Germany. He also serves
as an external advisor to the Open University, contributing to modules focused
on employability of biosciences graduates and employer expectations from
graduates in terms of bioinformatics training.

 

Further to the announcement on 19 March 2024, Suzanne Dilly will remain with
the Company for a one-month handover period to ensure business continuity and
will step down from the ValiRx Group after that period.

 

Dr Cathy Tralau-Stewart

 

Additionally, further to the announcement of 3 July 2024, the Company has
appointed Dr Cathy Tralau-Stewart as Executive Director with immediate effect.
 Cathy will also continue to hold the position of Chief Scientific Officer.

 

Pursuant to Rule 17 and Schedule 2(g) of the AIM Rules for Companies, the
following information is disclosed in respect of Catherine ("Cathy") Jane
Tralau-Stewart (aged 60):

 

 Current Directorships  Previous Directorships held in the past five years
 None                   None

 

Cathy Tralau-Stewart holds 66,666 ordinary shares representing approximately
0.05% per cent. of the Company's issued share capital and 150,000 options over
new ordinary shares in the Company.

 

There is no further information regarding Dr Cathy Tralau-Stewart required to
be disclosed under the AIM Rules.

 

Dr Suzanne Dilly, CEO of ValiRx commented "I'm delighted that after much
consideration, the structure of the new Board of Directors is taking shape.
I look forward to watching the Company's continued progress as the new team
develops the strategic direction of the company in their hands."

 

Dr Cathy Tralau-Stewart, CSO of ValiRx commented "I am pleased to join the new
Board of Directors at an exciting time for the Company. I look forward to
working with the new team and shareholders on the next phase of the Company."

 

Martin Gouldstone, Chairman of ValiRx commented "I am delighted to Chair
ValiRx at this pivotal time in the business's journey, and am excited to work
with Mark as the new proposed CEO and Cathy as an Executive Director to help
us to realise our potential."

 

The Directors of the Company take responsibility for this announcement.

 

 

*** ENDS ***

 

For more information, please contact:

 

 ValiRx plc                                        Tel: +44 (0) 115 784 0026

                                                   www.valirx.com

 Dr Suzanne Dilly, CEO                             Suzanne.Dilly@valirx.com (mailto:Suzanne.Dilly@valirx.com)

 V Formation (Public Relations)                    +44 (0) 115 787 0206

                                                   www.vformation.biz (http://www.vformation.biz/)

 Lucy Wharton - Senior PR Executive

 Sue Carr - Director                               lucy@vformation.biz

                                                   sue@vformation.biz
 Cairn Financial Advisers LLP (Nominated Adviser)  Tel: +44 (0) 20 7213 0880

 Liam Murray/Jo Turner/Ludovico Lazzaretti

 Shard Capital Partners LLP (Sole Broker)          Tel: +44 (0) 20 7186 9000

 Damon Heath

 

 

Notes for Editors

 

About ValiRx

 

ValiRx is a life science company focused on early-stage cancer therapeutics
and women's health, accelerating the translation of innovative science into
impactful medicines to improve patient lives.

ValiRx provides the scientific, financial, and commercial framework for
enabling rapid translation of innovative science into clinical development.

Using its extensive and proven experience in research and drug development,
the team at ValiRx selects and incubates promising novel drug candidates and
guides them through an optimised process of development, from pre-clinical
studies to clinic and investor-ready assets.

ValiRx connects diverse disciplines across scientific, technical, and
commercial domains, with the aim of achieving a more streamlined, less costly,
drug development process. The team works closely with carefully selected
collaborators and leverages the combined expertise required for science to
advance.

Lead candidates from ValiRx's portfolio are outlicensed or partnered with
investors through ValiRx subsidiary companies for further clinical development
and commercialisation.

ValiRx listed on the AIM Market of the London Stock Exchange in October 2006
and trades under the ticker symbol: VAL.

For further information, visit: www.valirx.com (http://www.valirx.com/)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAEAEXLASLLEAA